DAVID R. BETHUNE - Corporate Board Profile

VERU INC.

Filing Date	Source Excerpt
2006-02-27	The Board's Audit Committee is comprised of Dr. Frank (Chairperson), Mr. Bethune and Mr. Kerber. ... The Nominating and Corporate Governance Committee is comprised of Mr. Bethune (Chairman) and Mr. Walton. ... Individual directors who are not officers of the Company receive $1,000 for attendance in person at each meeting of the Board of Directors or meeting of a committee of which he or she is a member.
2007-02-20	Mr. Bethune has served as a Director of the Company since January 1996. He is currently a member of the Board of Directors of the CAMBREX Corporation, a life sciences company dedicated to providing products and services that accelerate and improve the discovery and commercialization of human therapeutics.
2008-02-20	Mr. Bethune has served as a Director of the Company since January 1996. ... The Board's Audit Committee is comprised of Dr. Frank (Chairperson), Mr. Bethune and Mr. Kerber. ... The Nominating and Corporate Governance Committee is comprised of Mr. Bethune (Chairman) and Mr. Walton. ... Director Summary Compensation Table shows total compensation for David Bethune as $30,261.
2009-02-24	Mr. Bethune has served as a Director of the Company since January 1996. He is currently Executive Chairman of Zila, Inc., an oral cancer screening company. Additionally, he is a member of the Board of Directors of the CAMBREX Corporation, a life sciences company dedicated to providing products and services that accelerate and improve the discovery and commercialization of human therapeutics.
2010-02-26	Mr. Bethune has served as a Director of the Company since January 1996. ... The chart below identifies the members of each of these committees as of the date of this Proxy Statement ... David R. Bethune ... Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee ... Director Summary Compensation Table ... David R. Bethune ... Total: $25,555.
2011-02-28	David R. Bethune has served as a Director of the Company since January 1996. The chart below identifies the members of each of these committees as of the date of this Proxy Statement, along with the number of meetings held by each committee during the fiscal year ended September 30, 2010: David R. Bethune - Audit Committee, Compensation Committee, Nominating and Corporate Governance Committee.
2012-02-24	The chart below identifies the members of each of these committees as of the date of this Proxy Statement, along with the number of meetings held by each committee during the fiscal year ended September 30, 2011: ... David R. Bethune X X X * ... The following table provides information concerning the compensation paid by the Company in fiscal 2011 to each of its directors who are not executive officers of the Company. ... David R. Bethune $33,000 $121,800 $154,800
2013-02-25	Mr. Bethune has served as a Director of the Company since January 1996. He was Chairman of Zila, Inc., an oral cancer screening company, from August 2007 to September 2009 and Chief Executive Officer of Zila, Inc. from March 2008 to September 2009. He served as a member of the Board of Directors of the CAMBREX Corporation, a life sciences company dedicated to providing products and services that accelerate and improve the discovery and commercialization of human therapeutics, from 2005 to March 2012. Mr. Bethune served as Chairman and Chief Executive Officer of Atrix Laboratories, Inc. from 1999 until his retirement in 2004. From 1997 to 1998, Mr. Bethune held the positions of President and Chief Operating Officer of the IVAX Corporation. From 1996 to 1997, Mr. Bethune was a consultant to the pharmaceutical industry. From 1995 to 1996, Mr. Bethune was President and Chief Executive Officer of Aesgen, Inc., a generic pharmaceutical company. From 1992 to 1995, Mr. Bethune was Group Vice President of American Cyanamid Company and a member of its Executive Committee until the sale of the company to American Home Products. He had global executive authority for human biologicals, consumer health products, pharmaceuticals and opthalmics, as well as medical research. In 1989 he became president of Lederle Laboratories, a division of American Cyanamid and held that position until 1992. Mr. Bethune is a founding trustee of the American Cancer Society Foundation. He is the founding chairman of the Corporate Council of the Children 2s Health Fund in New York City and served on the Arthritis Foundation Corporate Advisory Council.
2014-01-28	Mr. Bethune has served as a Director of the Company since January 1996. ... The Board of Directors has an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee. ... The chart below identifies the members of each of these committees as of the date of this Proxy Statement: David R. Bethune is a member of Audit, Compensation, and Nominating and Corporate Governance Committees. ... Director Summary Compensation Table shows fees earned of $10,000 for 2013.
2015-01-27	Mr. Bethune has served as a Director of the Company since January 1996. ... Mr. Bethune 2s impressive track record of achievements in leadership positions, including with public companies in the pharmaceutical and medical products industries, led to the conclusion that he should serve as a director of the Company and a member of the audit committee. ... The amount for Mr. Bethune represent fees paid for committee participation.
2016-01-26	Mr. Bethune has served as a Director of the Company since January 1996.
2017-01-27	David R. Bethune has served as a director of the Company since January 1996... Mr. Bethune's impressive track record... led to the conclusion that he should serve as a director of the Company and a member of the audit committee... Director Summary Compensation Table shows $120,391 in fees earned or paid in cash in 2016.
2017-06-21	In December 2013, the Board approved a new arrangement to compensate non-employee directors for their service as Board members. Each director received 14,382 shares of restricted stock, vesting in three tranches of 4,794 shares on the first, second and third anniversary of the grant, as compensation for a three year period. In addition, in fiscal 2016, Dr. Frank and Mr. Bethune each received fees for committee participation and each of Mr. Bethune and Ms. Felch received fees for providing special assistance to management in connection with designated projects. As described below, two of the Companys directors, William R. Gargiulo, Jr. and Sharon Meckes, received consulting fees during fiscal 2016. Director Summary Compensation Table The following table provides information concerning the compensation paid by the Company in fiscal 2016 to each person who served as a director during fiscal 2016 who was not an executive officer of the Company on September 30, 2016. David R. Bethune $ 120,391 - - - $ 120,391
2018-01-26	David R. Bethune has served as a director of the Company since January 1996. ... Mr. Bethune's impressive track record of achievements in leadership positions, including with public companies in the pharmaceutical and medical products industries, led to the conclusion that he should serve as a director of the Company and a member of the audit committee. ... The chart below identifies the current members of each of these committees, along with the number of meetings held by each committee during the fiscal year ended September 30, 2017: ... David R. Bethune - Audit Committee member ... Director Summary Compensation Table ... David R. Bethune - Total compensation $500,614.